Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Henriette Skribek"'
Autor:
Asa Gustafsson Jernberg, György Stuber, Henriette Skribek, Bruno Vanherberghen, Emilie Flaberg, Éva Oláh, Laszlo Szekely, Rita Ötvös, Laszlo Markasz
Publikováno v:
Biomedicine & Pharmacotherapy. 63:413-420
Rituximab is a humanized chimeric monoclonal antibody, targeted against the pan B cell marker CD20. It is frequently used to treat a variety of B cell lymphomas and immunosuppression associated lymphoproliferations such as posttransplant lymphoprolif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04ed4771756267278dcf31d63098578d
https://doi.org/10.1016/j.biopha.2008.08.009
https://doi.org/10.1016/j.biopha.2008.08.009
Autor:
Michael Uhlin, Henriette Skribek, Emilie Flaberg, Laszlo Szekely, Staffan Eksborg, Laszlo Markasz, György Stuber, Rita Ötvös, Éva Oláh
Publikováno v:
Journal of Immunotherapy. 31:283-293
Tumors are considered to be possible targets of immunotherapy using stimulated and expanded cytotoxic T-lymphocytes (CTL). It is important to consider the drug-induced effects when chemotherapeutic regimens and CTL-mediated immunotherapy is planned t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad8715347c254c6958cb65aa59844c2
https://doi.org/10.1097/cji.0b013e3181628b76
https://doi.org/10.1097/cji.0b013e3181628b76
Autor:
Laszlo Szekely, Katalin Dobra, Carl-Olof Hillerdal, Henriette Skribek, Eviane Yousef-Fadhel, Aytekin Celep, Adam Szulkin, Rita Ötvös, Anders Hjerpe
Publikováno v:
BMC Cancer
Background Patients with malignant mesothelioma have a poor prognosis and only 40% respond to first line treatment; a combination of pemetrexed and cisplatin or carboplatin. We used primary malignant mesothelioma cells and an ex vivo chemosensitivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f970c7b4498325dcf99e6653acdd8b
http://europepmc.org/articles/PMC4190467
http://europepmc.org/articles/PMC4190467
Autor:
Henriette Skribek, József Kónya, Staffan Eksborg, Rita Ötvös, Annunziata Gloghini, Antonino Carbone, Laszlo Szekely, Emilie Flaberg, Loránd L. Kis, Laszlo Markasz, Lajos Gergely
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 441 (2011)
BMC Cancer, Vol 11, Iss 1, p 441 (2011)
Background Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a34c260dac13ea4eeb4e800cfa4a5a9a
https://doi.org/10.1186/1471-2407-11-441
https://doi.org/10.1186/1471-2407-11-441
Autor:
Bruno Vanherberghen, Laszlo Markasz, Staffan Eksborg, György Stuber, Emilie Flaberg, Henriette Skribek, Ennio Carbone, Laszlo Szekely, Éva Oláh, Eva Klein
Publikováno v:
Molecular cancer therapeutics. 6(2)
Tumors are considered to be possible targets of immunotherapy using stimulated and expanded autologous or allogeneic natural killer (NK) cells mismatched for MHC class I molecules and inhibitory NK receptors. NK cell–based immunoadjuvant therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::203d0cb5ab2d6eb29c7d53b374ab3331
https://pubmed.ncbi.nlm.nih.gov/17308061
https://pubmed.ncbi.nlm.nih.gov/17308061
Autor:
Henriette Skribek, Emilie Flaberg, Laszlo Markasz, Laszlo Szekely, Staffan Eksborg, Éva Oláh, Å. Gustafsson Jernberg, György Stuber
Publikováno v:
Blood Reviews. 21:S98-S99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e96c3aeb61df9f69cd5ffcf691b1658c
https://doi.org/10.1016/s0268-960x(07)70114-5
https://doi.org/10.1016/s0268-960x(07)70114-5
Autor:
Laszlo Szekely, Henriette Skribek, Laszlo Markasz, Emilie Flaberg, Evah Olah, György Stuber, Staffan Eksborg, Asa Gustafsson Jernberg
Publikováno v:
BMC Cancer
BMC Cancer, Vol 6, Iss 1, p 265 (2006)
BMC Cancer, Vol 6, Iss 1, p 265 (2006)
Background Epstein-Barr virus (EBV) is the causative agent of immunosuppression associated lymphoproliferations such as post-transplant lymphoproliferative disorder (PTLD), AIDS related immunoblastic lymphomas (ARL) and immunoblastic lymphomas in X-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bf4e8bd5bcdabb7165ede28849dc1dd
http://europepmc.org/articles/PMC1664586
http://europepmc.org/articles/PMC1664586